Showing 9361-9370 of 19228 results for "".
- First Patient Enrolled in Nemolizumab Study for Chronic Itch Without Causehttps://reachmd.com/news/first-patient-enrolled-in-nemolizumab-study-for-chronic-itch-without-cause/2484883/Galderma announced the enrollment first patient in a phase II clinical trial investigating nemolizumab for the treatment of Chronic Pruritus of Unknown Origin (CPUO), according to a press release from the manufacturer. The tr
- Nemolizumab and the Future of Chronic Itch Therapy: A New Clinical Trial Takes Center Stagehttps://reachmd.com/news/nemolizumab-and-the-future-of-chronic-itch-therapy-a-new-clinical-trial-takes-center-stage/2484875/Nemolizumab's initiation in a Phase II trial marks the first targeted test of an IL‑31 antagonist in Chronic
- Understanding the Surge in Low-Capability Pediatric Hospitals: Implications for Healthcarehttps://reachmd.com/news/understanding-the-surge-in-low-capability-pediatric-hospitals-implications-for-healthcare/2484876/National inpatient data show the proportion of low-capability pediatric ho
- Revolutionizing Airway Management: AI Innovationshttps://reachmd.com/news/revolutionizing-airway-management-ai-and-acoustic-innovations/2484866/The mobile AI intubation system improves first-attempt intubation by 19.4% in trainee operators — a finding with immediate implications fo
- Transforming Pathology: AI and the Tumor Immune Landscapehttps://reachmd.com/news/transforming-pathology-ai-and-the-tumor-immune-landscape/2484867/GigaTIME shows that AI applied to routine hematoxylin and eosin (H&E) morphology can generate population-scale tumor immune maps that alter diagnostic and therapeutic workflows. By enabling spatially resolved proteomic inference from existing pathology assets, this approach converts sta
- Durvalumab After Chemoradiotherapy: Insights from the PACIFIC-5 Trial in Unresectable Stage III NSCLChttps://reachmd.com/news/durvalumab-after-chemoradiotherapy-insights-from-the-pacific-5-trial-in-unresectable-stage-iii-nsclc/2484868/The PACIFIC-5 trial shows that consolidation durvalumab meaningfully prolongs progression-free survival (PFS) for adults with unresectable stage III non–small-cell lung cance
- Therapeutic Advances in IgA Nephropathy: Atacicept and B-Cell Modulationhttps://reachmd.com/news/iga-nephropathy-atacicept-b-cell-modulation/2484843/Atacicept for the treatment of IgAN has entered the FDA accelerated Biologics License Application pathw
- Assessing Polyacrylamide Hydrogel for Stress Urinary Incontinence: Failure Rates and Durabilityhttps://reachmd.com/news/assessing-polyacrylamide-hydrogel-for-stress-urinary-incontinence-failure-rates-and-durability/2484856/A large-cohort evaluation of polyacrylamide hydrogel injections for stress urinary incontinence reports a 35.9% failure rate within two years, refining durability expectation
- Transformative Role of Next-Gen Infrared Fluorescence Imaging in Esophageal Surgeryhttps://reachmd.com/news/transformative-role-of-next-gen-infrared-fluorescence-imaging-in-esophageal-surgery/2484859/A team at the University of Hong Kong applied NIR-II fluorescence imaging during esophagectomy to generate real‑time, objective perfusion maps that can change intraoperative decision‑mak
- Update on Ianalumab and Eltrombopag: Phase III Findings and Implicationshttps://reachmd.com/news/ianalumab-eltrombopag-phase-iii/2484864/The phase 3 VAYHIT2 trial showed that ianalumab plus eltrombopag meaningfully